Brief: CASI Pharmaceuticals Acquires Global Intellectual Property Rights To Cleave Therapeutics' VCP/P97 Inhibitor CB-5339
20/07/2023 13:39
July 20 (Reuters) - CASI Pharmaceuticals Inc CASI.O :
* CASI PHARMACEUTICALS ACQUIRES GLOBAL INTELLECTUAL PROPERTY
RIGHTS TO CLEAVE THERAPEUTICS' VCP/P97 INHIBITOR CB-5339
* CASI PHARMACEUTICALS INC - CASI OBTAINED ALL RIGHTS AND
GLOBAL
INTELLECTUAL PROPERTY RIGHTS RELATED TO CB-5339
* CASI PHARMACEUTICALS INC - OBTAINED ALL REMAINING CB-5339
DRUG
SUBSTANCE AND DRUG PRODUCT
* CASI PHARMACEUTICALS INC - WILL ASSUME RESPONSIBILITY OF
UNITED
STATES ("US") CB-5339 INVESTIGATIONAL NEW DRUG ("IND")
APPLICATION
Source text for Eikon: ID:nPnbLty11a
Further company coverage: CASI.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on CASI Pharmaceuticals
See all newsBrief: Casi Pharmaceuticals Reports The Receipt Of Drug Registration Certificate For Thiotepa In China
CASI Pharmaceuticals Q3 revenue drops 60%, net loss widens
Brief: CASI Pharmaceuticals Inc Reports The Expiration Of Import Drug Registration License For Folotyn® In China
Casi Pharmaceuticals Inc Expected To Post A Loss Of 47 Cents A Share: Earnings Preview
Casi Pharmaceuticals Inc Reports Results For The Quarter Ended March 31: Earnings Summary